Pieris Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Consolidated Statements of Comprehensive Loss (Unaudited)

Consolidated Statements of Comprehensive Loss (Unaudited) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Statement of Comprehensive Income [Abstract]
Net loss	$ (3,704,734)us-gaap_NetIncomeLoss	$ (779,905)us-gaap_NetIncomeLoss
Other comprehensive loss
Foreign currency translation adjustments	(602,732)	(3,627)
Total other comprehensive loss, after tax	(602,732)	(3,627)
Comprehensive loss	$ (4,307,466)us-gaap_ComprehensiveIncomeNetOfTax	$ (783,532)us-gaap_ComprehensiveIncomeNetOfTax

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

- Definition

Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.

+ References + Details